https://orcid.org/0000-0001-6935-4470
References
- Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283x17745776.
- Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106–114.
- Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(2):140–146.
- Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033–1041.
- Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. WJG. 2018;24(14):1550–1561.
- Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol. 2008;22(4):601–616.
- Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(03):87–97.
- Kojima Y, Takeuchi T, Sanomura M, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study. Digestion. 2018;97(1):70–75.
- Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–251.
- Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–663.
- Shinozaki S, Osawa H, Kobayashi Y, et al. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan. Scand J Gastroenterol. 2018;53(8):897–904.
- Shinozaki S, Osawa H, Hayashi Y, et al. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2021;14(3):32.
- Feldman M, Richardson CT, Walsh JH. Sex-related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest. 1983;71(3):715–720.
- Helgadottir H, Metz DC, Lund SH, et al. Study of gender differences in proton pump inhibitor dose requirements for GERD: a double-blind randomized trial. J Clin Gastroenterol. 2017;51(6):486–493.
- Shinozaki S, Osawa H, Miura Y, et al. The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness. Biomed Rep. 2022;16(6):51.
- Waldum HL, Sørdal ØF, Mjønes PG. The enterochromaffin-like [ECL] cell-central in gastric physiology and pathology. Int J Mol Sci. 2019;20(10):2444.
- Sjöblom SM, Sipponen P, Karonen SL, et al. Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours. J Clin Pathol. 1989;42(4):371–377.
- Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut. 1992;33(10):1303–1306.